Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
WockhardtNSE:WOCKPHARMA +1.30%59 Gross Margin % is 67.05% as of Mar. 2026, which is 15% above its 10-year median of 58.12. GuruFocus rates NSE:WOCKPHARMA with a GF Score™ of 59/100 and a GF Value™ of ₹1,268.66 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 942 Drug Manufacturers companies, Wockhardt ranks better than 78.34% on this metric.
Gross Margin % is calculated as gross profit divided by its revenue. Wockhardt's Gross Profit for the
three
months ended in Mar. 2026 was ₹6,470 Mil. Wockhardt's Revenue for the
three
months ended in Mar. 2026 was ₹9,650 Mil. Therefore, Wockhardt's Gross Margin % for the quarter that ended in Mar. 2026 was 67.05%.
The historical rank and industry rank for Wockhardt's Gross Margin % or its related term are showing as below:
NSE:WOCKPHARMA'
s Gross Margin % Range Over the Past 10 Years
Min: 53.87 Med: 58.12 Max: 66.44
Current: 66.44
During the past 13 years, the highestGross Margin % of Wockhardt was 66.44%. The lowest was 53.87%. And the median was 58.12%.
NSE:WOCKPHARMA's Gross Margin % is ranked better than 78.34% of 942
companies
in the Drug Manufacturers industry
Industry Median: 48.54
vs NSE:WOCKPHARMA: 66.44
Wockhardt had a gross margin of 67.05% for the quarter that ended in Mar. 2026 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Wockhardt was 2.30% per year.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Wockhardt had a gross margin of 67.05% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Wockhardt Gross Margin % Related Terms
Wockhardt Gross Margin % Historical Data
* Premium members only.
The historical data trend for Wockhardt's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:WOCKPHARMA vs ZTS, UTHR: Gross Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Wockhardt's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Wockhardt Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Wockhardt's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Wockhardt's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Wockhardt (NSE:WOCKPHARMA) has a Gross Margin % of 67.05% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Wockhardt and its competitors. This is 15% above median its historical median of 58.12. Over the past decade, Wockhardt's Gross Margin % has ranged from 53.87 to 66.44. According to the industry distribution chart, Wockhardt ranks #204 out of 942 companies in the Drug Manufacturers industry, placing it in the top 21.7%.
Is Wockhardt's Gross Margin % too high?
Wockhardt's current Gross Margin % of 67.05% is 15% above median its 10-year median of 58.12. Over the past 10 years, this metric has ranged from a low of 53.87 to a high of 66.44. The Drug Manufacturers industry median Gross Margin % is 48.54. Wockhardt's value of 67.05% is 38.1% above this industry median. Based on the distribution chart, Wockhardt ranks #204 out of 942 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Wockhardt has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Wockhardt's Gross Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Wockhardt ranks #204 out of 942 companies for Gross Margin %. This places Wockhardt in the top 22% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 48.54. Wockhardt's value of 67.05% is 38.1% above this benchmark. Historically, Wockhardt's own Gross Margin % has ranged from 53.87 to 66.44 over the past decade. While the company's 10-year median is 58.12 vs. the industry median of 48.54, Wockhardt has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.54, based on 942 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Wockhardt's current Gross Margin % of 67.05% is 38.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Wockhardt and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Wockhardt's current Gross Margin % is 67.05%, which is 15% above median its own 10-year median of 58.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wockhardt stock overvalued right now?
Based on GuruFocus' analysis, Wockhardt (NSE:WOCKPHARMA) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹1,268.66, compared to a current price of ₹1,900.70 — trading 49.8% above its estimated fair value. The current Gross Margin % is 67.05%, which is 15% above median its 10-year median of 58.12 and 38.1% above the Drug Manufacturers industry median of 48.54. Wockhardt's overall GF Score™ is 59/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Wockhardt (NSE:WOCKPHARMA), the current Gross Margin % is 67.05% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Wockhardt (NSE:WOCKPHARMA) Overvalued in 2026?
Based on GuruFocus' analysis, Wockhardt stock appears to be overvalued.
The current stock price of ₹1,900.70 is trading 49.8% above its estimated GF Value™ of ₹1,268.66.
GuruFocus considers Wockhardt to be Significantly Overvalued.
Key valuation signals for NSE:WOCKPHARMA:
Gross Margin %: 67.05% (15% above median its 10-year median of 58.12)
GF Value™: ₹1,268.66 vs. price of ₹1,900.70 (49.8% above fair value)
Industry Position: 38.1% above the Drug Manufacturers median (#204 of 942)
No single metric tells the full story. See the NSE:WOCKPHARMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Wockhardt Ltd is a drug manufacturing company focusing on pharmaceutical and biotechnology products. The group is involved in new drug discovery, contract manufacturing, API, vaccines, and branded pharmaceuticals business. In addition, it operates a chain of super-specialty hospitals. Its novel antibiotic platform has various assets, such as Zaynich (WCK 5222); Miqnaf (Nafithromycin), a macrolide-class respiratory antibiotic; Ertapenem-Zidebactam (WCK 6777); Foviscu (WCK 2482), an antibiotic for Gram-negative infections; and Odrate (WCK 6777), among others. The group is mainly engaged in the pharmaceutical business, which is considered its only reportable business segment. Geographically, it generates maximum revenue from Europe, followed by India, the USA, and the Rest of the world.
59GF Score
Get the complete analysis for NSE:WOCKPHARMA
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:WOCKPHARMA has been successfully added to your 
